Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026), a clinical stage diagnostics company dedicated to improving outcomes for patients ...
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
AccuStem Sciences, Inc. (OTCQB: ACUT ), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback